Dinutuximab beta Drug Aliquot | Anti-GD2 | Therapeutic Antibody

Aliquoted from the original reference drug Quarziba®| Now available for research use

Aliquots of the reference drug Dinutuximab beta are now available as research consumables.

Dinutuximab beta (expressed in CHO) drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Dinutuximab Beta Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Qarziba® / Dinutuximab beta Reference Product

Drug nameQarziba®
INNDinutuximab beta
API typechimeric monoclonal IgG1 antibody
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
disialoganglioside 2 (GD2)

General functionDinutuximab beta is a chimeric monoclonal IgG1 antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Dinutuximab beta has been shown in vitro to bind to neuroblastoma cell lines known to express GD2 and to induce both complement dependent cytoxicity (CDC) and antibody dependent cell-mediated cytoxicity (ADCC). In the presence of human effector cells, including peripheral blood nuclear cells and granulocytes from normal human donors, dinutuximab beta was found to mediate the lysis of human neuroblastoma and melanoma cell lines in a dose-dependent manner.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Neurotoxicity associated to dinutuximab beta is likely due to the induction of mechanical allodynia that may be mediated by the reactivity of dinutuximab beta with the GD2 antigen located on the surface of peripheral nerve fibres and myelin.
Original license holder
EUSA Pharma (Netherlands) B.V. Beechavenue 54, 1119PW, Schiphol-Rijk Netherlands
Marketing authorisation numbers
Marketing authorisation holder
EUSA Pharma (Netherlands) B.V. Beechavenue 54, 1119PW, Schiphol-Rijk Netherlands
Name of the manufacturer of the biological active substance
Rentschler Biopharma SE Erwin-Rentschler-Strasse 21 Laupheim, Baden-Wuerttemberg 88471 Germany
Name and address of the manufacturer(s) responsible for batch releaseMillmount Healthcare Ltd Block 7, City North Business Campus Stamullen, Co. Meath K32 YD60 Ιreland
Max shelf life
Unopened vial: 3 years, Diluted solution (solution for infusion): 2 °C – 8 °C
Storage conditions
2°C – 8°C
List of excipients
Histidine Sucrose Polysorbate 20 Water for injections Hydrochloric acid (for pH adjustment)

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting